Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
OnKure Therapeutics, Inc. (OKUR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: OKUR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $34.2
1 Year Target Price $34.2
| 5 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -25.56% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 76.57M USD | Price to earnings Ratio 71.75 | 1Y Target Price 34.2 |
Price to earnings Ratio 71.75 | 1Y Target Price 34.2 | ||
Volume (30-day avg) 6 | Beta - | 52 Weeks Range 1.70 - 20.00 | Updated Date 05/17/2025 |
52 Weeks Range 1.70 - 20.00 | Updated Date 05/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.08 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE 71.75 | Forward PE - | Enterprise Value 565252 | Price to Sales(TTM) - |
Enterprise Value 565252 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.57 | Shares Outstanding 12652900 | Shares Floating 4190656 |
Shares Outstanding 12652900 | Shares Floating 4190656 | ||
Percent Insiders 1.45 | Percent Institutions 96.85 |
Analyst Ratings
Rating 3 | Target Price 34.2 | Buy 1 | Strong Buy 5 |
Buy 1 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
OnKure Therapeutics, Inc.
Company Overview
History and Background
OnKure Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of small molecule drugs targeting critical signaling pathways in cancer. Founded in 2015, OnKure's milestones include advancing its lead compounds into clinical trials and securing funding to support ongoing research and development.
Core Business Areas
- Drug Development: Focuses on creating and advancing small molecule drugs targeting cancer signaling pathways.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates in cancer patients.
- Research and Discovery: Engages in research to identify novel drug targets and develop new therapeutic approaches for cancer treatment.
Leadership and Structure
OnKure is led by a team of experienced biopharmaceutical executives and scientists. Its organizational structure includes departments focused on research, drug development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- OKI-179: OKI-179 is a selective PI3Ku03b1 inhibitor in clinical development for the treatment of advanced solid tumors. Market share data is not publicly available as it is still in clinical trials. Competitors include companies developing other PI3K inhibitors such as Novartis (BYI.SW).
- OKI-219: OKI-219 is a pre-clinical stage compound targeting histone deacetylases (HDACs). Market share data is not applicable as it is still in pre-clinical development. Competitors include companies developing other HDAC inhibitors such as Merck (MRK).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, high R&D costs, and stringent regulatory requirements. The oncology market is a major segment, driven by the increasing prevalence of cancer and the demand for innovative therapies.
Positioning
OnKure Therapeutics, Inc. is positioned as a company focused on developing innovative small molecule drugs for cancer treatment. Its competitive advantages include its experienced management team, proprietary drug discovery platform, and promising clinical pipeline.
Total Addressable Market (TAM)
The global oncology market is estimated to be in the hundreds of billions of dollars. OnKure Therapeutics, Inc. is positioned to capture a portion of this TAM through the successful development and commercialization of its drug candidates.
Upturn SWOT Analysis
Strengths
- Experienced management team
- Proprietary drug discovery platform
- Promising clinical pipeline
- Strong intellectual property portfolio
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Reliance on third-party manufacturers
- Early-stage company with no marketed products
Opportunities
- Partnerships and collaborations with larger pharmaceutical companies
- Expansion of clinical trials to new indications
- Out-licensing of drug candidates
- Acquisition by a larger company
Threats
- Clinical trial failures
- Competition from other pharmaceutical companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- Novartis (BYI.SW)
- Merck (MRK)
- Johnson & Johnson (JNJ)
- Bristol Myers Squibb (BMY)
Competitive Landscape
OnKure Therapeutics, Inc. faces intense competition from established pharmaceutical companies. Its competitive advantages include its innovative drug discovery platform and promising clinical pipeline. Its disadvantages include its limited financial resources and lack of marketed products.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is not available as OnKure Therapeutics, Inc. is a private company.
Future Projections: Future projections are not publicly available as OnKure Therapeutics, Inc. is a private company.
Recent Initiatives: Recent initiatives include advancing OKI-179 into clinical trials and securing funding to support ongoing research and development.
Summary
OnKure Therapeutics is a private biopharmaceutical company focused on cancer therapeutics. It boasts innovative research and a promising pipeline, but faces challenges common to early-stage companies, including limited resources and clinical trial risk. Its success hinges on advancing its lead compounds and securing strategic partnerships. The company's future trajectory depends on navigating the competitive landscape and achieving clinical validation.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- ClinicalTrials.gov
- Industry Reports
- Analyst Reports (estimates based on publically available info.)
Disclaimers:
This analysis is based on limited publicly available information and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About OnKure Therapeutics, Inc.
Exchange NASDAQ | Headquaters Boulder, CO, United States | ||
IPO Launch date 2024-10-07 | President, CEO & Director Dr. Nicholas A. Saccomano Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 46 | Website https://onkuretherapeutics.com |
Full time employees 46 | Website https://onkuretherapeutics.com | ||
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.